Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
Browsing: GLP-1
University of Alberta researchers investigate why semaglutide weight loss varies, focusing on metabolic adaptation and individual energy metabolism differences.
A new review suggests GLP-1 medications may influence brain function, though clinical trials for Alzheimer’s have shown mixed results regarding cognitive preservation.
Figures show 419 prescriptions for weight-loss jabs were issued to children under 18 in England last year, including 10 for those under 12.
Heineken has warned UK pubs that the rise of weight-loss drugs could reduce beer sales, advising venues to promote smaller serves and low-alcohol options.
New research from Rutgers University identifies a small increase in the risk of ischemic optic neuropathy among patients taking GLP-1 medications like Ozempic and Wegovy.
A multinational study finds that GLP-1 weight loss drugs are linked to significantly higher rates of nail detachment and hair loss, though researchers say the changes are usually benign.
Patients sue Novo Nordisk claiming GLP-1 drugs caused NAION. FDA reviews adverse event data as courts decide if warnings are needed.
The World Health Organization has issued new guidelines advising against the use of obesity drugs for children under 10, prioritizing lifestyle changes over medication.
